biolitec® with booth at Medica in Düsseldorf from 14. till 17. November – biolitec® presents new development HOLA™-laser therapy for gynaecology to expert audience as well as modern laser therapies LHP™ and ELVeS Radial™
Jena, November 16th, 2012 – The world“s largest medical technology trade fair, Medica, is held again in Düsseldorf this year. biolitec® will present its wide variety of laser systems and application accessories for painless laser-based methods of treatment at its information booth G 46 in Hall 10.
As one of this year“s outstanding new developments, the revolutionary laser system HOLA™ (Hysteroscopic Outpatient Laser Applications) has been developed for the treatment of myomas in gynaecology. Myomas are benign tumours which affect every fourth to sixth woman in Europe, mostly between 30 and 50 years of age. Myomas can cause a variety of complications which can considerably reduce the patient“s quality of life. The laser therapy against myomas provides a gentle and painless alternative to conventional methods in gynaecology. While applied, the feeding artery is getting closed by a radial emitting laser fibre, thus no particles or other foreign substances are needed during the therapy. Thereby, HOLA™ does not damage the endometrium, and it enables a painless treatment under local anaesthesia. The laser energy allows for precise control of the tissue vaporisation with no bleeding and immediately visible results. In the aftermath, the patient can get back to normal activities immediately.
For the treatment of haemorrhoids of higher grades, biolitec® has developed the so called Laserhaemorrhoidoplastie (LHP™) during which nodal dilatations are reduced from within by the laser. Thereby, the sensitive anoderm and the mucosa are protected to a maximum. The natural anatomic structure stays intact, and risks such as anal stenoses are excluded. As no cuts or stitches are necessary, postoperative pain appears significantly less often in comparison to conventional surgical procedures, and recovery is accelerated. Furthermore, biolitec® provides the minimally invasive treatment option FiLaC™ for the treatment of fistulas.
For a couple of years now, the well-established ELVeS®-laser system for the treatment of varicose veins constitutes a milestone in phlebology. During the treatment, the affected veins are treated with laser energy, and the vein is absorbed by the body. The injection site for the fibre optics is the only injection site needed, so little or no scars are left. In comparison to conventional vein therapies, such as e.g. stripping, the ELVeS Radial™-laser therapy features the prevention of postoperative discomfort. The minimally invasive procedure is applied outpatient under local anaesthesia within 30 to 45 minutes. After the procedure, the patient can quickly return to normal activities. Furthermore, biolitec® sets new pace in minimally invasive laser therapies with the innovative fibres ELVeS Radial slim™ and ELVeS Radial 2ring™. With their individual specific advantages, both fibres offer a wide range for the treatment of different anatomies in the treatment of varicose veins.
About biolitec®:
biolitec® AG is one of the leading companies worldwide in the field of medical laser treatments und the only provider that possesses all relevant core competencies – photosensitizers, laser devices and optical fibres – in the field of photodynamic therapy (PDT). Besides the laser treatment of cancer with Foscan®, biolitec® primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS Radial™ (Endo Laser Vein System) the laser system is most often used worldwide for the treatment of varicose veins. Ceralas® HPD laser therapy enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in urology. Gentle laser treatments in the fields of proctology, ENT, orthopaedics, gynaecology as well as ophtalmology also belong to the business field of biolitec®. biolitec® is listed in the Prime Standard (ISIN DE0005213409). Further information at www.biolitec.de.
Press contact:
Jörn Gleisner
Telefon: +49 (0) 6172/27159-20
Telefax: +49 (0) 6172/27159-69
E-Mail: joern.gleisner@biolitec.com
biolitec® AG is one of the leading companies worldwide in the field of medical laser treatments und the only provider that possesses all relevant core competencies – photosensitizers, laser devices and optical fibres – in the field of photodynamic therapy (PDT). Besides the laser treatment of cancer with Foscan®, biolitec® primarily researches on minimally-invasive and gentle laser treatments and markets them. ELVeS Radial™ (Endo Laser Vein System) the laser system is most often used worldwide for the treatment of varicose veins. Ceralas® HPD laser therapy enables a gentle treatment of e.g. benign prostatic hyperplasia (BPH) in urology. Gentle laser treatments in the fields of proctology, ENT, orthopaedics, gynaecology as well as ophtalmology also belong to the business field of biolitec®. biolitec® is listed in the Prime Standard (ISIN DE0005213409). Further information at www.biolitec.de.
Kontakt:
biolitec AG
Jörn Gleisner
Otto-Schott-Straße 15
07745 Jena
+49 (0) 6172/27159-20
info@biolitec.de
http://www.biolitec.de
Pressekontakt:
fr financial relations gmbh
Jörn Gleisner
Louisenstraße 97
61348 Bad Homburg
+49 (0) 6172/ 27159-20
joern.gleisner@biolitec.com
http://www.biolitec.de